Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 6/20 | 0.35 |
| ▸ | DCK | P27707 | 9/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21912594 | 0.78 | AURKA (0.34) | — | |
| SCHEMBL4254350 | 0.77 | EP300 (0.34) | EP300 | |
| SCHEMBL28349363 | 0.77 | ALB (0.39) | ALBEP300DCK | |
| SCHEMBL15872011 | 0.77 | KDM5B (0.33) | — | |
| SCHEMBL17041816 | 0.77 | ALB (0.39) | ALBEP300DCK | |
| SCHEMBL2852193 | 0.76 | ALB (0.40) | ALBEP300DCK | |
| SCHEMBL18080744 | 0.75 | ALB (0.41) | ALBEP300DCK | |
| SCHEMBL16869991 | 0.75 | AURKA (0.33) | — | |
| SCHEMBL2194330 | 0.75 | — | — | |
| SCHEMBL13586939 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183852-A9 | PHOSPHONATE PRODRUGS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023183852-A1 | PHOSPHONATE PRODRUGS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022127914-A1 | NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021098379-A1 | PHENYLALANINE-AMIDATED NUCLEOTIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 广东中科药物研究有限公司 | 2021-05-27 | — | — | WO | disclosed |
| WO-2021034373-A1 | CONJUGATES OF GUIDE RNA-CAS PROTEIN COMPLEX | ZHONG MINGHONG (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20210054371-A1 | Conjugates of Guide RNA-Cas Protein Complex | ZHONG MINGHONG (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2020263888-A1 | CANNABINOID CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2009115927-A2 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2009-09-24 | — | — | WO | disclosed |
| EP-1573019-B1 | STEREOSELECTIVE PROCESS FOR THE PRODUCTION OF DIOXOLANE NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| WO-2008087558-A2 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2008-07-24 | — | — | WO | disclosed |
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | GIFU UNIVERSITY (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | GIFU UNIVERSITY (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | NSUN2, RNMT, RNGTT | ALB 3563/4885EP300 4786/4885DCK 56/4885 |
| US-20210054371-A1 | Conjugates of Guide RNA-Cas Protein Complex | SARNP, SLIRP, NSUN3 | ALB 272/4885EP300 3318/4885DCK 727/4885 |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | ALB 3831/4885EP300 4849/4885DCK 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.